Vestmark Advisory Solutions Inc. Has $3.74 Million Holdings in Recursion Pharmaceuticals, Inc. $RXRX

Key Points

• Vestmark Advisory Solutions Inc. reduced its holdings in Recursion Pharmaceuticals by 16.4%, owning approximately 0.18% of the company after selling 138,915 shares.
• Recursion Pharmaceuticals reported a revenue of $19.10 million for the quarter, which exceeds analyst estimates of $15.38 million, but missed earnings estimates with ($0.41) earnings per share.
• Analysts have a consensus rating of "Hold" on Recursion Pharmaceuticals, with an average target price of $7.00, while Needham & Company maintains a "buy" rating with an $8.00 price objective.

Vestmark Advisory Solutions Inc. reduced its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 16.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 706,239 shares of the company's stock after selling 138,915 shares during the quarter. Vestmark Advisory Solutions Inc. owned 0.18% of Recursion Pharmaceuticals worth $3,736,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. ARK Investment Management LLC increased its position in Recursion Pharmaceuticals by 7.6% in the 1st quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company's stock valued at $184,174,000 after acquiring an additional 2,469,104 shares during the period. Softbank Group CORP. bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth $99,152,000. Kinnevik AB publ boosted its stake in shares of Recursion Pharmaceuticals by 12.8% during the 1st quarter. Kinnevik AB publ now owns 13,434,171 shares of the company's stock worth $71,067,000 after acquiring an additional 1,528,503 shares in the last quarter. Novo Holdings A S bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth $68,375,000. Finally, Laurion Capital Management LP bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth $16,611,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Needham & Company LLC reissued a "buy" rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday, July 8th. Morgan Stanley started coverage on Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 target price for the company. Two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $7.00.

Recursion Pharmaceuticals Stock Down 7.8%

RXRX traded down $0.43 during trading on Tuesday, reaching $5.09. 20,005,249 shares of the stock traded hands, compared to its average volume of 24,890,428. The stock has a market cap of $2.21 billion, a price-to-earnings ratio of -2.86 and a beta of 0.93. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $3.79 and a fifty-two week high of $12.36. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 3.58. The stock's 50-day simple moving average is $5.49 and its two-hundred day simple moving average is $5.81.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.06). The firm had revenue of $19.10 million for the quarter, compared to analyst estimates of $15.38 million. Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. Recursion Pharmaceuticals's revenue for the quarter was up 33.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.40) EPS. As a group, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.